AUTOIMMUNITY, published by Taylor & Francis Ltd, is an influential journal dedicated to advancing the understanding of autoimmune diseases through rigorous research and scholarly discourse. With an ISSN of 0891-6934 and an E-ISSN of 1607-842X, this journal serves as a key resource for immunologists, medical professionals, and students engaged in investigating the complex mechanisms underpinning autoimmunity. Operating from the United Kingdom, it offers valuable insights into immunological and allergic phenomena, achieving respectable Scopus rankings in both Immunology and Allergy (106/233, Q3) and Immunology and Microbiology (125/236, Q2). Covering a broad spectrum of topics since its inception in 1988, AUTOIMMUNITY encourages the dissemination of innovative research findings and aims to enhance collaborative efforts within the field. While it currently adopts a conventional access model, the journal's commitment to quality and excellence positions it as a vital platform for those looking to engage with cutting-edge research in immunology.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Case Reports in Immunology, published by HINDAWI LTD, is an esteemed open-access journal that has been contributing to the field of immunology since its launch in 2011. With both ISSN 2090-6609 and E-ISSN 2090-6617, the journal provides a platform for researchers to publish detailed case reports that explore diverse immunological conditions and novel treatment approaches. This journal is crucial for clinicians, researchers, and students alike, seeking to broaden their understanding of immunology's practical applications and advances. As of 2023, it holds a Q3 ranking in Immunology and Q2 in Immunology and Allergy, reflecting its growing relevance and contribution to the field. Additionally, it is indexed in Scopus, where it ranks #178 in Immunology and Allergy and #192 in Immunology and Microbiology, enhancing its visibility and impact. With a comprehensive accessibility model, the journal is dedicated to disseminating knowledge widely and enriching discussions in immunological research.

Welcome to the International Journal of Immunopathology and Pharmacology, a premier publication dedicated to advancing the fields of immunology and pharmacology. Published by SAGE Publications Inc., this Open Access journal has been a vital resource since its inception in 1989, providing an expansive platform for innovative research and comprehensive reviews until 2024. With a strong focus on the mechanisms of immune responses and therapeutic developments, our journal stands out with a 2023 impact factor reflected in its Q3 ranking in Immunology and Allergy, and a Q2 ranking in Pharmacology. The journal's Scopus rankings highlight its significance, ranking #174 in Pharmacology, #141 in Medicine, and #156 in Immunology, all affirming its role in contributing to the broader scientific community. Through rigorous peer review and a commitment to high-quality research, the International Journal of Immunopathology and Pharmacology continues to be an essential resource for scientists, healthcare professionals, and students striving to enhance their knowledge and understanding in these critical fields.

Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

Welcome to the European Journal of Immunology, a premier peer-reviewed journal dedicated to advancing the field of immunology and allergy research. Established in 1971 and published by Wiley, this esteemed journal has been consistently ranked in the top quartile (Q1) across its categories, highlighting its significant impact within the scientific community. With an impressive Scopus ranking, the journal occupies the 64th position in Immunology and Allergy and the 74th in the broader sector of Immunology and Microbiology, demonstrating its vital role in driving innovation and knowledge in immunological studies. The European Journal of Immunology publishes high-quality original research, comprehensive reviews, and insightful commentary, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to understanding the complexities of the immune system. Although not an open-access journal, it offers various subscription options to ensure that institutions and individuals can access pivotal research that shapes the future of immunology.

Expert Review of Clinical Immunology is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, dedicated to advancing the field of immunology, with a particular focus on clinical applications and therapeutic developments. With an ISSN of 1744-666X and an E-ISSN of 1744-8409, this journal has made a significant impact in the scientific community, evidenced by its Q2 ranking in both Immunology and Allergy for 2023, as well as solid placements in Scopus ranks (73/233 and 87/236 in their respective categories). Operating from the United Kingdom, the journal publishes comprehensive reviews designed to keep researchers, clinicians, and students updated on cutting-edge advancements and trends in immunology. Although it is not an open-access journal, its high impact factor and rigorous editorial standards reinforce its relevance and importance in providing high-quality, evidence-based information. As we progress towards 2024, Expert Review of Clinical Immunology remains a vital resource for anyone involved in the immunological sciences, facilitating knowledge exchange and fostering innovative research within this critical area of medicine.

Acta Dermatovenerologica Alpina Pannonica et Adriatica, published by the Dermatovenereological Society of Slovenia, stands as an important peer-reviewed journal in the fields of dermatology, infectious diseases, and general medicine. Established in 1994, this journal has built a solid reputation over the years, achieving a Q3 ranking in 2023 within its respective categories, which highlights its contribution and relevance in the academic community. With an ISSN of 1318-4458 and E-ISSN of 1581-2979, it aims to disseminate new research findings, review articles, and case reports that impact clinical practice and promote knowledge in dermatovenereology throughout the Alpine and Adriatic regions. Located in Ljubljana, Slovenia, the journal actively supports open access to its publications, ensuring that valuable insights are available to a global audience, which is crucial for advancing medical research and practice. The dedication to quality and scientific rigor makes Acta Dermatovenerologica Alpina Pannonica et Adriatica a must-read for researchers, practitioners, and students aiming to stay informed on the latest advancements in dermatology and related disciplines.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.

The Journal of Translational Autoimmunity, published by ELSEVIER, stands at the forefront of research in the ever-evolving fields of autoimmunity and immunology. With an ISSN of 2589-9090, this Open Access journal has been committed to facilitating the dissemination of high-quality research since its inception in 2019. Nestled in the Netherlands, it serves as a vital platform for researchers and professionals focused on translating innovative findings into practical applications for autoimmune disorders. The journal has achieved notable recognition, securing a Q2 quartile ranking in both the Immunology and Immunology and Allergy categories, showcasing its influence within the academic community, currently ranking 70th out of 233 in Medicine: Immunology and Allergy and 83rd out of 236 in Immunology and Microbiology: Immunology. By engaging with cutting-edge studies and fostering collaborative research, the Journal of Translational Autoimmunity is not only a cornerstone of academic inquiry but also a beacon of hope for clinical advancements in the management of autoimmune conditions. Researchers, professionals, and students alike are encouraged to contribute and stay abreast of the latest discoveries that hold the potential to transform patient care.